Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice

Neurobiology of Aging

Volumn 34, Issue 10, 2013, Pages 2379-2388

  Löffler, Tina ^a,b   Flunkert, Stefanie ^a   Havas, Daniel ^a   Sántha, Miklós ^c   Hutter Paier, Birgit ^a   Steyrer, Ernst ^b   Windisch, Manfred ^a  

^a QPS Austria ^*  (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Alzheimer's disease; Apolipoprotein B 100; Brain; Hyperlipidemia; Transgenic mice; Vascular risk factor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOACCUMULATION; BRAIN BLOOD VESSEL; BRAIN DISEASE; COGNITION; CONTROLLED STUDY; FEMALE; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ALZHEIMER'S DISEASE; APOLIPOPROTEIN B-100; BRAIN; HYPERLIPIDEMIA; TRANSGENIC MICE; VASCULAR RISK FACTOR;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, WILD; APOLIPOPROTEIN B-100; BRAIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COGNITION; FEMALE; GENE EXPRESSION; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RISK FACTORS;

EID: 84879887721     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.04.008     Document Type: Article

References (32)

1. Bereczki E., Bernat G., Csont T., Ferdinandy P., Scheich H., Santha M. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J.Proteome Res. 2008, 7:2246-2252.
2. Bjelik A., Bereczki E., Gonda S., Juhasz A., Rimanoczy A., Zana M., Csont T., Pakaski M., Boda K., Ferdinandy P., Dux L., Janka Z., Santha M., Kalman J. Human apoB overexpression and a high-cholesterol diet differently modify the brain APP metabolism in the transgenic mouse model of atherosclerosis. Neurochem. Int. 2006, 49:393-400.
3. Bonomini F., Tengattini S., Fabiano A., Bianchi R., Rezzani R. Atherosclerosis and oxidative stress. Histol. Histopathol. 2008, 23:381-390.
4. Breslow J.L. Mouse models of atherosclerosis. Science 1996, 272:685-688.
5. Burns A., Byrne E.J., Maurer K. Alzheimer's disease. Lancet 2002, 360:163-165.
6. Callow M.J., Stoltzfus L.J., Lawn R.M., Rubin E.M. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2130-2134.
7. Callow M.J., Verstuyft J., Tangirala R., Palinski W., Rubin E.M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J.Clin. Invest. 1995, 96:1639-1646.
8. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
9. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 2001, 64:575-611.
10. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
11. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
12. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
13. Harman D. Alzheimer's disease pathogenesis: role of aging. Ann. N. Y. Acad. Sci. 2006, 1067:454-460.
14. Havas D., Hutter-Paier B., Ubhi K., Rockenstein E., Crailsheim K., Masliah E., Windisch M. Alongitudinal study of behavioral deficits in an AbetaPP transgenic mouse model of Alzheimer's disease. J.Alzheimers Dis. 2011, 25:231-243.
15. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?. Exp. Gerontol. 2011, 46:225-232.
16. Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995, 45:1092-1096.
17. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S., Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 2001, 30:119-128.
18. Kowalska A. [The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease]. Neurologia i neurochirurgia polska 2004, 38:405-411.
19. Kuo Y.M., Emmerling M.R., Bisgaier C.L., Essenburg A.D., Lampert H.C., Drumm D., Roher A.E. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem. Biophys. Res. Commun. 1998, 252:711-715.
20. Lenart N., Szegedi V., Juhasz G., Kasztner A., Horvath J., Bereczki E., Toth M.E., Penke B., Santha M. Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice. PLoS One 2012, 7:e46007.
21. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58:730-735.
22. Martins I.J., Berger T., Sharman M.J., Verdile G., Fuller S.J., Martins R.N. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J.Neurochem. 2009, 111:1275-1308.
23. Miyakawa T. Vascular pathology in Alzheimer's disease. Psychogeriatrics 2010, 10:39-44.
24. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J.Neurosci. Methods 1984, 11:47-60.
25. Rockenstein E., Mallory M., Mante M., Sisk A., Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J.Neurosci. Res. 2001, 66:573-582.
26. Skoog I., Kalaria R.N., Breteler M.M. Vascular factors and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1999, 13(suppl 3):S106-S114.
27. Sparks D.L., Martin T.A., Gross D.R., Hunsaker J.C. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc. Res. Techn. 2000, 50:287-290.
28. Sule Z., Mracsko E., Bereczki E., Santha M., Csont T., Ferdinandy P., Bari F., Farkas E. Capillary injury in the ischemic brain of hyperlipidemic, apolipoprotein B-100 transgenic mice. Life Sci. 2009, 84:935-939.
29. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001, 32:181-184.
30. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 2002, 30:552-557.
31. Yao Y., Zhukareva V., Sung S., Clark C.M., Rokach J., Lee V.M., Trojanowski J.Q., Pratico D. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology. 2003, 61:475-478.
32. Zou K., Gong J.S., Yanagisawa K., Michikawa M. Anovel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J.Neurosci. 2002, 22:4833-4841.